cached image

Alan P. Kozikowski

Affiliations: 
University of Illinois at Chicago, Chicago, IL, United States 
Area:
medicinal chemistry
Website:
http://foto.pharm.uic.edu/mcp/people/kozikowski_ap.html
Google:
"Alan Kozikowski"
Bio:

Alan P. Kozikowski was born in 1948 in Menominee, MI. He received his Ph.D. degree from the University of California, Berkeley, under the supervision of the late Professor W. G. Dauben. After postdoctoral work with Professor E. J. Corey at Harvard University, Dr. Kozikowski began his independent career at the University of Pittsburgh. After 14 years there, he spent 3 years at the Mayo Clinic and then moved on to the Georgetown University Medical Center, where he is the Director of the Drug Discovery Program. Dr. Kozikowski's interests are in the areas of drug abuse, medications development, second messenger based therapeutics for cancer, and novel chemical interventions for the treatment of Alzheimer's disease.

Mean distance: 7.15
 
SNBCP

Parents

Sign in to add mentor
William G. Dauben grad student 1974 UC Berkeley
 (Studies related to the synthesis of sesquiterpenes)
Elias James Corey post-doc 1974-1976 Harvard

Children

Sign in to add trainee
Arun K. Ghosh grad student 1985 University of Pittsburgh
Jay Kalin grad student 2012 University of Illinois, Chicago
Jia Zhou post-doc 2001-2003
Marinella Roberti research scientist Mayo Clinic
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zhou H, Lin S, Li X, et al. (2021) Serum miR-222 is independently associated with atrial fibrillation in patients with degenerative valvular heart disease. Bmc Cardiovascular Disorders. 21: 98
Tavares MT, Kozikowski AP, Shen S. (2020) Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors. European Journal of Medicinal Chemistry. 209: 112887
Noonepalle S, Shen S, Ptacek J, et al. (2020) Rational Design of Suprastat, a Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. Journal of Medicinal Chemistry
Shen S, Svoboda M, Zhang G, et al. (2020) Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor. Acs Medicinal Chemistry Letters. 11: 706-712
Tan L, Zhou Q, Yan W, et al. (2020) Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. Journal of Medicinal Chemistry
Picci C, Wong VSC, Costa CJ, et al. (2020) HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Experimental Neurology. 113281
Cortés Llorca L, Li R, Yon F, et al. (2020) ZEITLUPE facilitates the rhythmic movements of Nicotiana attenuata flowers. The Plant Journal : For Cell and Molecular Biology
Raynaud C, Daher W, Roquet-Banères F, et al. (2020) Synergistic interactions of indole-2-carboxamides and β-lactam antibiotics against . Antimicrobial Agents and Chemotherapy
Shen S, Kozikowski AP. (2019) A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019). Expert Opinion On Therapeutic Patents
Raynaud C, Daher W, Johansen M, et al. (2019) Active benzimidazole derivatives targeting the MmpL3 transporter in . Acs Infectious Diseases
See more...